Novel strategies to overcome the blood-brain barrier in triple-negative breast cancer brain metastases.
Y, F., H, Z., S, T., & M, T. (2026). Novel strategies to overcome the blood-brain barrier in triple-negative breast cancer brain metastases.. The Lancet. Oncology. https://doi.org/10.1016/S1470-2045(26)00146-4
Y F, H Z, S T, M T. Novel strategies to overcome the blood-brain barrier in triple-negative breast cancer brain metastases.. The Lancet. Oncology. 2026; doi: 10.1016/S1470-2045(26)00146-4
Y F, H Z, S T, et al. Novel strategies to overcome the blood-brain barrier in triple-negative breast cancer brain metastases.[J]. The Lancet. Oncology. 2026. DOI: 10.1016/S1470-2045(26)00146-4.
@article{y2026,
author = {Fan Y and Zhang H and Tang S and Toi M},
title = {Novel strategies to overcome the blood-brain barrier in triple-negative breast cancer brain metastases.},
journal = {The Lancet. Oncology},
year = {2026},
doi = {10.1016/S1470-2045(26)00146-4},
note = {PMID: 42372753},
}
TY - JOUR AU - Fan Y AU - Zhang H AU - Tang S AU - Toi M TI - Novel strategies to overcome the blood-brain barrier in triple-negative breast cancer brain metastases. T2 - The Lancet. Oncology PY - 2026 DO - 10.1016/S1470-2045(26)00146-4 AN - PMID:42372753 ER -
Triple-negative breast cancer-the most aggressive breast cancer subtype-has a high propensity for brain metastases, with limited treatments and poor prognosis. The blood-brain barrier, long viewed as an impermeable therapeutic sanctuary, is the core barrier to effective care. This Review advocates a key paradigm shift for clinical and translational research: from merely circumventing the blood-brain barrier to actively targeting and exploiting its biology. We delineate triple-negative breast cancer-specific mechanisms of blood-brain barrier breach and evaluate emerging therapies via a clinically actionable three-pillar framework: physical and focal blood-brain barrier disruption, biological blood-brain barrier exploitation, and microenvironmental modulation. We also summarise advances in preclinical models for blood-brain barrier-targeted drug development. Synthesising the latest preclinical and clinical evidence, this Review provides a translational roadmap for unmet clinical needs, emphasising that integrated, blood-brain barrier-centric strategies are crucial to improving patient outcomes.